---
title: "JPM Raises HANSOH PHARMA  TP to HKD50 as Interim Results Beat"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297487520.md"
description: "JPMorgan raised Hansoh Pharma's target price to HKD50 from HKD45, maintaining an Overweight rating. This adjustment follows the company's first-half results beating expectations, with revenue up 11.7% YoY to RMB8.3 billion and net profit surging 35.8% to a record RMB4.26 billion. JPM upgraded full-year collaboration revenue forecasts by 4%, citing strong performance in innovative drugs and increased visibility regarding upcoming product approvals."
datetime: "2026-08-31T08:50:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297487520.md)
  - [en](https://longbridge.com/en/news/297487520.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297487520.md)
generator: "portal-rs"
---

# JPM Raises HANSOH PHARMA  TP to HKD50 as Interim Results Beat

JPM released a research report saying that HANSOH PHARMA (03692.HK) -1.380 (-3.758%) Short selling $117.59M; Ratio 18.135% 's results for the first half beat expectations, with revenue rising 11.7% YoY to RMB8.304 billion, mainly driven by innovative drugs and collaboration revenue, whose contribution to revenue increased to 85.4%. Net profit during the period grew 35.8% YoY to RMB4.258 billion, a record high for a half-year period, although part of the gain came from one-off income related to unlisted venture capital investments in the life sciences sector.

Management disclosed during the results briefing that five new products are expected to receive approval next year, while a cumulative total of 30 new products are expected to be approved by 2030. JPM said this could strengthen market confidence in the progress of its pipeline. Based on the first-half results, JPM raised its forecast for HANSOH PHARMA's full-year collaboration revenue by 4%. Due to approvals of new products and improved visibility, the broker also slightly raised its long-term revenue forecasts. The TP was lifted from HKD45 to HKD50, while the Overweight rating was maintained.(gc/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-31 16:25.)

### Related Stocks

- [03692.HK](https://longbridge.com/en/quote/03692.HK.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [Did NMPA’s Acceptance of HS-20093 Just Shift Hansoh Pharmaceutical Group's (SEHK:3692) Oncology Narrative?](https://longbridge.com/en/news/298117536.md)
- [Hansoh Pharma says China NMPA accepts HS-20093 BLA for small cell lung cancer](https://longbridge.com/en/news/297754887.md)
- [HANSOH PHARMA  1H26 Net Profit Up 35.8% YoY to RMB4.258B; Interim DPS Hiked 23% to HKD0.285](https://longbridge.com/en/news/297019908.md)
- [Hansoh Pharmaceutical cuts convertible bond conversion price to HK$56.54 per share](https://longbridge.com/en/news/297047890.md)
- [JPMorgan hires healthcare banker David Blais from Guggenheim, sources say](https://longbridge.com/en/news/298063714.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**